Invivyd Inc. (NASDAQ: IVVD) announced plans to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 for treating individuals ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE